Article Text

Download PDFPDF

112 Trends in treatment of systemic lupus erythematosus and lupus nephritis: 2006–2016
Free
  1. Ali Duarte-Garcia,
  2. Cynthia Crowson,
  3. Chowdhary Vaidehi,
  4. Shreyasee Amin,
  5. Kenneth Warrington,
  6. Eric Matteson and
  7. Nilay Shah
  1. Mayo Clinic

Abstract

Background Glucocorticoids, anti-malarials and conventional immunosuppressive agents have been the mainstay of therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN); more recently biologic agents have been introduced for their treatment. We evaluated utilization trends in SLE and LN therapy over the past decade.

Methods Using 2006–2016 data from a large administrative database of commercially insured and Medicare Advantage beneficiaries, we identified patients with SLE and a subset of patients with LN based on validated claims-based algorithms. Included patients had at least one year of enrollment in the cohort. We estimated the annual age- and sex- standardized proportion of patients who filled prescriptions for at least one of the drugs of interest (table).

Results A total of 30 787 patients with prevalent SLE were identified, of whom 5267 had LN. Mean age (SD) was 49.3 (14.1) years for SLE and 51.9 (17.2) years for LN. Ninety percent were female, 61.0% White, 17.4% Black, 11.2% Hispanic, 3.0% Asian and 7.0% other/unknown. Use and time trends of therapeutic agents for 2006–2016 are included in the table. Anti-malarials were the most frequently used drug class, with some temporal change over the course of the study; 50.1% in 2006 to 47.5% in 2016 for SLE, and 38.8% in 2006 to 45.1% 2016 for LN. Prednisone was the second most frequently used drug, decreasing from 40.0% in 2006 to 34.7% in 2016; use of methylprednisolone and other systemic glucocorticoids increased during that time period. Methotrexate was the most commonly used nonbiologic immunosuppressive drug in SLE (8.0%), while MMF was most frequently prescribed in LN (15.0%). Cyclophosphamide use declined over the last decade for SLE (1.2% to 0.3% in 2016) and LN (4.2% to 1.3% in 2016). Belimumab was the most commonly used biologic for SLE with a slight uptrend since approval. Rituximab use increased in SLE and was the most commonly used biologic for LN. At any point in time ~24% of the patients were not receiving any of the medications of interest.

Abstract 112 Table 1

Proportion of patients with SLE and LN receiving any of the drugs of interest (%)

Conclusions Over the past decade, a substantial proportion of patients with SLE and LN continued to receive glucocorticoids. The proportion of patients receiving nonbiologic immunosuppressants remained stable, however there was a progressive decline in the use of cyclophosphamide. Since 2011 the proportion of patients receiving rituximab is higher than for cyclophosphamide. The increasing use of rituximab, which is not currently approved for SLE or LN, highlights the need to clarify its therapeutic role in these diseases.

Funding Source(s): None

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.